# reload+after+2024-01-23 05:46:16.548103
address1§200 Berkeley Street
address2§Office 19th Floor
city§Boston
state§MA
zip§02116
country§United States
phone§857 702 9600
website§https://www.neurobopharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
fullTimeEmployees§2
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Hyung-Heon  Kim', 'age': 48, 'title': 'CEO, President, Principal Executive & Director', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 54217, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Marshall H. Woodworth', 'age': 65, 'title': 'Acting CFO, Principal Financial Officer & Principal Accounting Officer', 'yearBorn': 1958, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Mi-Kyung  Kim', 'title': 'Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Robert  Homolka', 'title': 'Senior Vice President of Clinical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§-0.664
currency§USD
dateShortInterest§1702598400
forwardEps§-3.69
exchange§NCM
quoteType§EQUITY
shortName§NeuroBo Pharmaceuticals, Inc.
longName§NeuroBo Pharmaceuticals, Inc.
firstTradeDateEpochUtc§1470403800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§df3dac6a-eed3-3175-b85d-a432fd732c3e
gmtOffSetMilliseconds§-18000000
targetHighPrice§48.0
targetLowPrice§48.0
targetMeanPrice§48.0
targetMedianPrice§48.0
recommendationMean§1.0
recommendationKey§strong_buy
numberOfAnalystOpinions§1
quickRatio§5.472
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
